Experts say that teamwork among biotech companies, investors and state and federal lawmakers will lead toward discoveries and position the industry for long-term growth in Central Virginia and elsewhere. Approximately 600 biotech leaders, investors and industry advocates, including legislatures from Charlottesville-area companies and the University of Virginia, met a week ago to share ideas and strategies at the Mid-Atlantic Bio Conference held in Bethesda, Md, September 27-28, 2012.
Peregrine Pharmaceuticals (NASDAQ:PPHM) continued to plunge more after a series of law investigation announcements. For this company, a return on equity of -530.39 percent was realized due to the financial situation. Last twelve months earnings per share reached a value of -$0.47. The stock closed at $0.860, down -0.170 points or -16.50% from previous close and at a distance of -74.36% from 20-day simple moving average.
Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) tumbled after providing preliminary data from Phase 1/2 Study of TH-302. Shares of this company traded down -12.25% during trading yesterday, hitting $7.10. The stock has a 52 week low of $1.18 and a 52 week high of $9.28. The company has a market cap of $350.22 million. P/S ratio is 165.97 and P/C ratio 5.26. The beta value is 1.69. THLD’s RSI amounts to 35.60.
Gilead Sciences, Inc. (NASDAQ:GILD) surpassed 52-week high price after Bernstein upgraded the stock to outperform rating. The company has a market value of $51.02 billion. It employs 4,500 people, over the last 12 months has generated revenue of $9.01 billion and has a net income of $2.56 billion. The firm’s operating margin is 41.32 percent and net profit margin 28.22 percent. The latest closing price of its shares moved up 14.74% from the 50-day moving average.
Despite hitting new high, Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) shares closed down after Bank of America Merrill Lynch reaffirmed buy rating and lifted its price target on the stock. In the last trading session, the stock’s price moved 42.37% above their 200 day moving average, changing hands as low as $23.74 per share. The stock is currently trading 15.68% up their SMA 50. The worst hit in its 52 week range is $7.72 per share, with $25.14 being the 52 week best price, which compares with a latest closing price of $23.88. The Beta of this stock is 1.29.
